Liver cancer superantigen immunogene therapy agent

Abstract

A super-antigen immune gene treater for liver cancer is characterized by that the liver cancer cell specific regulation sequence mediated super-antigen moleculae and co-stimulation moleculae are target expressed in liver cancer cells to specifically enhance the immunogenicity of cancer cell and the recognition action to immunoeffect cells. after the treater is injected to cancer region, it can effectively kill cancer cells.

Description

1. Technical field

[0001] The invention relates to genetic engineering technology, in particular to a liver cancer superantigen immune gene therapy agent. 2. Background technology

[0002] Hepatocellular carcinoma (liver cancer) is one of the most common malignancies. At present, surgical resection is still the main treatment for liver cancer, but recurrence and metastasis often occur after surgery, and the mortality rate remains high. Tumor gene therapy is a new biological treatment method that has emerged since the latter part of the last century. American biotechnology companies have invested about 1 billion US dollars in gene therapy research and clinical practice, accounting for more than 60% of the total research funding (National Reference Center for Bioethics Literature, USA), our country started relatively late in gene therapy and is in a relatively lagging state. There has not been any successful research report on gene therapy for liver cancer. 3. Contents of t...